Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
In a prospective, open-label study of 30 male Special Operations veterans with mostly mild traumatic brain injury, a treatment protocol combining magnesium and oral ibogaine (MISTIC), given with other supportive care, was associated with large, statistically significant improvements in functioning and in clinician-rated PTSD, depression and anxiety scores immediately after…
Researchers had 13 healthy adults take Hericium erinaceus powder every day for seven days. They tested blood with routine blood and serum chemistry tests and checked gut bacteria using 16S rRNA gene sequencing. After the week, the gut bacterial community showed higher within-sample diversity and higher levels of several bacteria…
Researchers reviewing ibogaine and its chemical relatives say these drugs point to a new way to treat substance use disorders by blocking a brain receptor called α3β4 nicotinic acetylcholine receptor (nAChR). Animal studies found ibogaine and some derivatives reduced self-use of drugs like morphine, cocaine, alcohol, and nicotine. But ibogaine…
This paper reviews early evidence that raising body temperature in a controlled way — called whole-body hyperthermia — may affect brain problems seen in diseases like Alzheimer's, Parkinson's, Huntington's and in some cases of Long COVID. Heating the body to fever-like levels can boost special protective proteins (heat shock proteins),…
In a randomized, double-blind, placebo-controlled crossover trial, researchers tested one single dose of 650 mg guayusa extract (AmaTea® Max), 1 g Nordic Lion’s Mane, and a placebo in healthy adults. Tests were done before ingestion and at 1 and 2 hours after. Guayusa (AMT) led to several faster and more…
This paper describes a planned study to test whether eating a specific mushroom powder can help prevent thinking and memory problems in people aged 45–74 who are at higher risk for dementia. The plan has two parts: a 10-year follow-up of an existing group of over 1,000 older adults, and…
